News | September 12, 2023
Indian pharma industry to witness 8-10% revenue growth in fiscal 2024: CRISIL
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)